Affimed’s (AFMD) Overweight Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Affimed (NASDAQ:AFMD) in a research note released on Tuesday,Benzinga reports.

A number of other equities research analysts also recently commented on AFMD. Stifel Nicolaus reduced their price objective on shares of Affimed from $5.00 to $4.00 and set a “hold” rating for the company in a research report on Friday, November 15th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Affimed in a report on Friday, November 15th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $16.00.

Affimed Stock Performance

NASDAQ:AFMD opened at $3.00 on Tuesday. Affimed has a 12-month low of $2.90 and a 12-month high of $8.95. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.93 and a quick ratio of 1.93. The stock’s 50 day simple moving average is $3.45 and its 200-day simple moving average is $4.48.

Affimed (NASDAQ:AFMD) last posted its quarterly earnings data on Thursday, September 5th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.09). The firm had revenue of $0.17 million during the quarter, compared to analysts’ expectations of $1.67 million. Affimed had a negative net margin of 7,836.26% and a negative return on equity of 193.84%. As a group, analysts expect that Affimed will post -4.25 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in AFMD. FMR LLC grew its holdings in shares of Affimed by 30.0% in the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 4,086 shares during the period. Choreo LLC purchased a new stake in Affimed during the second quarter worth $54,000. Intellectus Partners LLC grew its holdings in Affimed by 12.2% in the third quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock valued at $317,000 after purchasing an additional 10,250 shares during the last quarter. Jane Street Group LLC purchased a new position in shares of Affimed in the third quarter valued at $44,000. Finally, Point72 Asset Management L.P. raised its stake in shares of Affimed by 4.6% during the 3rd quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock worth $1,152,000 after buying an additional 15,108 shares during the last quarter. 30.82% of the stock is owned by hedge funds and other institutional investors.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.